Similarly, AMG 317 failed to show clinical efficacy in patients with moderate to severe asthma [211] and trials with soluble recombinant IL-4R, altrakincept, used in a nebulized form, were discontinued in phase 1/2 [212]. Here, IL4R is linked to asthma.